karbala journal of pharmaceutical sciences

Thyroid cancer is the most common endocrine malignancy and its incidence continues to rise yearly .Thyroid carcinoma, in most cases, presents clinically as a solitary nodule or as a dominant nodule within a multinodular thyroid gland. it is very important to identify one or more markers to distinguish thyroid cancer from different types of thyroid disease., Oxidative stress is considered to be involved in the pathophysiology of all cancers.Interleukin-10 is a pleiotropic cytokine with both anti-inflammatory and anti-angiogenic properties that may be involved in the pathogenesis of autoimmune thyroid diseases. Thyroid cancer cells of all histological variants produce considerable amounts of IL-10, which might be important in the pathological features of thyroid cancer and/or outcome. Our study aimed to evaluate IL-10 and oxidative stress markers, Malondiaaldehyde and super oxide dismutase (MDA&SOD) levels in sera of patients with CA thyroid and their close relatives compared to healthy control.and to study the correlation of these markers before and after the thyroidectomy operation compared with 1st to 2nd relatives and healthy controls. This 89study includes Thirty (30) subjects as the study sample is made of: 1) 15 diagnosed cases of CA thyroid before surgery and post-surgical treatment, 2) 15 cases of their 1st, or 2nd degree relatives; and 30 healthy subjects (control) would be recruited from surgical clinic in Al-Imamain Al- kadhimain city hospital from October 2014 up to December of 2016.Serum IL-10 was estimated using an Enzyme-Linked Immunosorbant Assay ( ELISA ) technique. Serum MDA levels were assessed using thiobarbituric acid (TBA) method of Buege and Aust , while SOD was measured by Burtis and Ashwood, using modified photochemical Nitroblue Tetrazolium (NBT) method utilizing sodium cyanide as peroxidase inhibitor.Analysis of serum levels demonstrated significantly increased levels of IL-10 in cancer patients between pre-thyroidectomy and post-thyroidectomy(p<0.01) and significantly increased compared with control groups (p<0.001) , SOD activities of pre-thyroidectomy, post-thyroidectomy and control groups were not different (p>0.05).In post- thyroidectomy MDA levels decreased compared to prethyroidectomy levels( p<0.01).also thyroid cancer significantly decreased compared with control groups (p<0.001). Although post-thyroidectomy MDA levels significantly decreased, but still higher than the healthy control group.its concluded that cytokine profile (IL-10) is reflective of an inflammatory immune response. These cytokines may increase the pathogenicity of thyroid CA and may be useful as biomarkers or targets for therapy. SOD does not seem to change with thyroid cancer and thyroidectomy but MDA change.IL-10 & MDA may be a more useful for monitoring the clinical status of thyroid cancer patients.

Benign prostatic hyperplasia (BPH) alone or with lower urinary tract symptoms (LUTS) was of the major public health problem among men especially over 55. In this trial serum interleukins six& eight (6&8) were estimated, also determining renal function test (urea& creatinine) and uric acid. Highly sensitive C- reactive protein (hs- CRP) and total prostate specific antigen (t- PSA) were measured in BPH, BPH+ LUTS and control groups. The result of this trial illustrate the elevation of all biochemical & immunological parameters significantly in both A&B groups when compared with control (P value= 0.002, 0.001 &0.000) except uric acid in group A appear insignificantly increased with group C (P value=0.477).
In conclusion the study predict the increasing in selected parameters very well & clearly so this help in diagnosis and management of BPH alone or with LUTS accompanies with inflammation which play an important role to transfer the benign disease to malignant. The aim of this study is to evaluate some clinical parameters especially hs- CRP that not previous used as a marker in the blood of elderly individuals who suffered from BPH with or without LUTS be of assistance in diagnosing & managing once in order to decrease the complication and severity of patient status which may convert the benign to malignant cases.